Cargando…

A PET-CT study on neuroinflammation in Huntington’s disease patients participating in a randomized trial with laquinimod

Microglia activation, an indicator of central nervous system inflammation, is believed to contribute to the pathology of Huntington’s disease. Laquinimod is capable of regulating microglia. By targeting the translocator protein, (11)C-PBR28 PET-CT imaging can be used to assess the state of regional...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roussakis, Andreas-Antonios, Gennaro, Marta, Gordon, Mark Forrest, Reilmann, Ralf, Borowsky, Beth, Rynkowski, Gail, Lao-Kaim, Nicholas P, Papoutsou, Zoe, Savola, Juha-Matti, Hayden, Michael R, Owen, David R, Kalk, Nicola, Lingford-Hughes, Anne, Gunn, Roger N, Searle, Graham, Tabrizi, Sarah J, Piccini, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069663/ https://www.ncbi.nlm.nih.gov/pubmed/37020532 http://dx.doi.org/10.1093/braincomms/fcad084

Ejemplares similares

Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells
por: Dobson, Lucianne, et al.
Publicado: (2016)

PET Imaging in Huntington’s Disease
por: Roussakis, Andreas-Antonios, et al.
Publicado: (2015)

Dopamine Transporter Density in de novo Parkinson’s Disease Does Not Relate to the Development of Levodopa-Induced Dyskinesias
por: Roussakis, Andreas-Antonios, et al.
Publicado: (2019)

Brain Imaging and Impulse Control Disorders in Parkinson’s Disease
por: Roussakis, Andreas–Antonios, et al.
Publicado: (2019)

Parkinson’s disease laterality: a (11)C-PE2I PET imaging study
por: Roussakis, Andreas-Antonios, et al.
Publicado: (2020)

Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease
por: Garcia-Miralles, Marta, et al.
Publicado: (2016)

Laquinimod treatment in the R6/2 mouse model
por: Ellrichmann, Gisa, et al.
Publicado: (2017)

Author Correction: Laquinimod treatment in the R6/2 mouse model
por: Ellrichmann, Gisa, et al.
Publicado: (2019)

Laquinimod Inhibits Inflammation-Induced Angiogenesis in the Cornea
por: Li, Zuohong, et al.
Publicado: (2020)

Laquinimod Supports Remyelination in Non-Supportive Environments
por: Nyamoya, Stella, et al.
Publicado: (2019)

Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review
por: Kolb-Sobieraj, Channa, et al.
Publicado: (2014)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

Astrogliosis in aging and Parkinson’s disease dementia: a new clinical study with (11)C-BU99008 PET
por: Mohamed, Mohamed A, et al.
Publicado: (2022)

Stimulating neural plasticity with real‐time fMRI neurofeedback in Huntington's disease: A proof of concept study
por: Papoutsi, Marina, et al.
Publicado: (2017)

Laquinimod reduces neuroaxonal injury through inhibiting microglial activation
por: Mishra, Manoj Kumar, et al.
Publicado: (2014)

Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake
por: Gentile, Antonietta, et al.
Publicado: (2018)

Pharmacological treatment of chorea in Huntington’s disease–good clinical practice versus evidence-based guideline
por: Reilmann, Ralf
Publicado: (2013)

Laquinimod in the treatment of multiple sclerosis: a review of the data so far
por: Thöne, Jan, et al.
Publicado: (2016)

Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model
por: Wilmes, Anna T., et al.
Publicado: (2018)

Characterizing patient compliance over six months in remote digital trials of Parkinson’s and Huntington disease
por: Cohen, Shani, et al.
Publicado: (2018)

The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study
por: Frank, Samuel, et al.
Publicado: (2022)

Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study
por: Klöppel, Stefan, et al.
Publicado: (2015)

Longitudinal expression changes are weak correlates of disease progression in Huntington’s disease
por: Mitchell, Christopher T, et al.
Publicado: (2020)

Laquinimod prevents cuprizone-induced demyelination independent of Toll-like receptor signaling
por: Kramann, Nadine, et al.
Publicado: (2016)

Targeting “bad” B cells in multiple sclerosis: Could laquinimod be part of the armamentarium?
por: Forsthuber, Thomas G., et al.
Publicado: (2016)

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune Inflammation in the CNS
por: Rothhammer, Veit, et al.
Publicado: (2021)

Longitudinal functional connectivity changes related to dopaminergic decline in Parkinson’s disease
por: Li, Weihua, et al.
Publicado: (2020)

Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression
por: Varrin-Doyer, Michel, et al.
Publicado: (2016)

Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree
por: Cutter, Gary R., et al.
Publicado: (2016)

Laquinimod attenuates inflammation by modulating macrophage functions in traumatic brain injury mouse model
por: Katsumoto, Atsuko, et al.
Publicado: (2018)

Laquinimod Modulates Human Astrocyte Function and Dampens Astrocyte-Induced Neurotoxicity during Inflammation
por: Colombo, Emanuela, et al.
Publicado: (2020)

Dissociable effects of age and Parkinson’s disease on instruction-based learning
por: Parkin, Beth L, et al.
Publicado: (2021)

Activity or connectivity? A randomized controlled feasibility study evaluating neurofeedback training in Huntington’s disease
por: Papoutsi, Marina, et al.
Publicado: (2020)

Restorative Strategies in Movement Disorders: the Contribution of Imaging
por: Lao-Kaim, Nicholas P., et al.
Publicado: (2017)

A Computational Cognitive Biomarker for Early-Stage Huntington’s Disease
por: Wiecki, Thomas V., et al.
Publicado: (2016)

Assessment of Motor Symptoms and Functional Impact in Prodromal and Early Huntington Disease
por: Vaccarino, Anthony L, et al.
Publicado: (2011)

Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination
por: Brück, Wolfgang, et al.
Publicado: (2012)

Transcriptomic Impact of IMA-08401, a Novel AHR Agonist Resembling Laquinimod, on Rat Liver
por: Prokopec, Stephenie D., et al.
Publicado: (2019)

Neuroinflammation in Huntington’s disease: From animal models to clinical therapeutics
por: Jia, Qingqing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cmkbspil5v63cufrr6mlgag1a2